Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 feb 2014 - 07:39
Statutaire naam
Galapagos NV
Titel
Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative colitis
Bericht
Mechelen, Belgium; 17 February 2014 - Galapagos NV (Euronext: GLPG) announced today that patient recruitment has been completed for the clinical Proof of Concept study with GLPG0974. GLPG0974 presents a novel mode of action for the treatment of ulcerative colitis, a debilitating inflammatory bowel disease. The efficacy and safety of GLPG0974 are being evaluated during a 28-day treatment period. Topline results from this study are expected in June 2014. GLPG0974 is fully proprietary to Galapagos.
Datum laatste update: 09 februari 2025